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Abstract
About 77.9 million (1 in 4) American adults have high blood pressure. High blood pressure is the primary cause of left ventricular
hypertrophy (LVH), which represents a strong predictor of future heart failure and cardiovascular mortality. Previous studies have
shown an altered metabolic proﬁle in hypertensive patients with LVH. The goal of this study was to identify blood metabolomic LVH
biomarkers by 1H NMR to provide novel diagnostic tools for rapid LVH detection in populations of hypertensive individuals. This
cross-sectional study included 48 hypertensive patients with LVHmatched with 48 hypertensive patients with normal LV size, and 24
healthy controls. Two-dimensional targeted M-mode echocardiography was performed to measure left ventricular mass index.
Partial least squares discriminant analysis was used for the multivariate analysis of the 1H NMR spectral data. From the 1H NMR-
based metabolomic proﬁling, signals coming from methylene (–CH2–) and methyl (–CH3) moieties of aliphatic chains from plasma
lipids were identiﬁed as discriminant variables. The –CH2–/–CH3 ratio, an indicator of the mean length of the aliphatic lipid chains, was
signiﬁcantly higher (P<0.001) in the LVH group than in the hypertensive group without LVH and controls. Receiver operating
characteristic curve showed that a cutoff of 2.34 provided a 52.08% sensitivity and 85.42% speciﬁcity for discriminating LVH (AUC=
0.703, P-value<0.001). We propose the –CH2–/–CH3 ratio from plasma aliphatic lipid chains as a biomarker for the diagnosis of left
ventricular remodeling in hypertension.
Abbreviations: 1H NMR = proton nuclear magnetic resonance, AUC = area under the curve, BMI = body mass index, –CH2– =
methylene, –CH3 = methyl, DBP = diastolic blood pressure, E/A = early/late ventricular ﬁlling velocities ratio, E/Ea = early diastolic
transmitral velocity to early mitral annular diastolic velocity ratio, LA = left atrium, LV = left ventricular, LVEF = left ventricular ejection
fraction, LVH = left ventricular hypertrophy, LVIDd = left ventricular internal diameter at end-diastole, LVM = left ventricular mass,
LVMI = left ventricular mass index, PET = positron electron tomography, PLS-DA = partial least square discriminant analysis, PWTd
= left ventricular posterior wall thickness at end-diastole, ROC = receiver operating characteristic, SBP = systolic blood pressure,
SWTd = septum wall thickness at end-diastole.
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Hypertension is the principal etiology of pathologic left
ventricular hypertrophy (LVH).[1] Pressure-dependent hemody-
namic overload induces left ventricular remodeling as an adaptive
response to minimize wall stress. Over time, LVH becomes
maladaptive and emerges as a strong and independent risk factor
for cardiovascular morbidity (e.g., heart failure, coronary artery
disease, cerebrovascular accidents, ventricular arrhythmia) and
mortality.[2–6] Indeed, studies indicate that in 20%[7] to 36%[8] of
chronic hypertensive patients, the myocardium undergoes
profound structural remodeling, characterized by enhanced
cardiomyocyte growth, increased rate of cardiomyocyte apopto-
sis, accumulation of ﬁbrosis, and microcirculatory changes.
This structural remodeling disrupts myocardial excitation–-
contraction coupling and eventually leads to heart failure.[9,10]
The increase in the cardiomyocyte stretching is the main factor
that induces the cardiac hypertrophic growth. However, a host of
nonhemodynamic factors (neuroendocrine stimulation, renin
angiotensin aldosterone system, endotelin-1) substantially con-
tribute to modulating the hypertrophic response.[11] Notable
relevance in the regulation of LVHhas been found in the defective
vasodilatation due to desensitization of b adrenergic receptors by
an increase of G-protein coupled receptor kinases.[12–15]
During hypertensive LVH, metabolic changes have been
observed in the cardiac muscle, which switches its preference
from fatty acids to glucose for ATP generation. Rodent models of
spontaneous hypertension,[16] and humans with essential
hypertension,[17,18] display a decrease in myocardial fatty acid
uptake and an increased reliance on glucose and lactate for
energy provision. In the acute setting, this shift is considered
beneﬁcial to the contractile function because enhanced glucose
metabolism allows the heart to cope with the increased workload
by producing more ATP per molecule of oxygen consumed.[19]
However, chronic hypertension induces the reactivation of the
fetal gene program and renders persistent metabolic remodel-
ing.[20] Lastly, in advanced pathological hypertrophy, myocardi-
al glucose metabolism is also decreased due to the development of
insulin resistance, leaving the heart unable to generate sufﬁcient
ATP to sustain the high workload.[21]
Because LVH commonly precedes cardiac failure in patients
with hypertension, the early detection of left ventricular (LV)
remodeling could potentially optimize health care for hyperten-
sive patients at risk of developing heart failure. Echocardiogra-
phy and electrocardiography are presently the most readily
available tools for identifying LVH, though they may prove to be
time consuming for physicians and costly for patients. Several
studies have proposed the use of positron electron tomography
(PET) scans to detect the early metabolic alterations in
myocardial tissue during LVH.[22,23] However, PET scanning
cannot be used for routine LVH detection because of high
running costs, the fact that it exposes the patient to ionizing
radiation and to radioactive substances, and because the
equipment is only available in a minority of medical centers.
Circulating biomarkers have also been investigated in hyperten-
sive heart disease (i.e., LVH secondary to hypertension): the
quantiﬁcation of cardiotrophin-1,[24] annexin A5,[25] and
propeptide of procollagen type I[26] has been proposed for
screening of the disease, but none of these biomarkers are
currently used in clinical practice due to their low sensitivity or
lack of speciﬁcity.
We aimed to identify biomarkers of LV remodeling in the
plasma of hypertensive patients using untargeted metabolomics.2Metabolomics, a high-throughput technology widely used in
clinical and epidemiological research, has successfully been
employed to screen for cardiovascular biomarkers.[27] Myocar-
dial metabolism is the ﬁrst responder to changes in cardiac
homeostasis and therefore it may identify metabolites (small
molecules of atomic mass <1.5kDa) as biomarkers of cellular
stress, even before structural or functional changes can be
observed by clinical imaging techniques. For example, pattern-
recognition techniques applied to proton nuclear magnetic
resonance (1H NMR) spectra of human serum correctly diagnose
the presence and severity of coronary artery disease.[28]
In this study, our purpose was to identify metabolomic
biomarkers in the plasma of hypertensive patients that could
indicate the presence of LV remodeling.2. Methods
2.1. Subjects
The study population was enrolled in the cardiology department
of Rangueil Hospital, Toulouse, France to constitute the
Identiﬁcation Of Blood Markers For Asymptomatic Ventricular
Dysfunction (IBLOMAVED) cohort. During the period 2007 to
2010, among 600 screened patients, 221 presented with
hypertension. According to the inclusion and exclusion criteria
of the study, and in order to match the cardiovascular risk factors
in the 2 hypertensive groups, the ﬁnal number of patients
included was 120. Patients were sorted into 3 groups for the
present analysis: 24 healthy controls, 48 patients with hyperten-
sion and normal LV size, and 48 patients with hypertension and
LV hypertrophy. The 2 comparative groups of hypertensive
patients were matched for age, obesity, body mass index (BMI),
diabetes, and dyslipidemia. Inclusion criteria were age over 18
years, signed informed consent, fasting blood sampling, and
presence of appropriate echocardiographic data. Exclusion
criteria included presence of acute or chronic heart failure, any
form of cardiomyopathy (e.g., familial obstructive hypertrophic
cardiomyopathy, dilated cardiomyopathy, or toxic cardiomyop-
athy), myocardial necrosis, heart rhythm problems, active
smoking, or smoking cessation in the past 3 years, hemoglobin-
opathies, septicemia, hepatitis, or kidney failure requiring
dialysis. All subjects underwent a complete cardiac evaluation,
including medical history, physical examination, blood pressure
measurement, and echocardiography. This research protocol
was registered in a clinical database (ClinicalTrials.gov
NCT01024049) and conforms to the ethical guidelines of the
1975 Declaration of Helsinki. The protocol was approved by the
institution’s human research (COSSEC) and regional ethics
committee (Comité de Protection des Personnes (CPP) #
DC2008-452). Written informed consent was obtained from
all participants.2.2. Blood pressure measurement
All hypertensive subjects underwent a 24-hour ambulatory blood
pressure measurement recorded with validated ambulatory
recorders (TM 2420 and TM 2421, A & D Engineering, CA,
San Jose.[29] A trained nurse ﬁtted a cuff on the left arm of the
patients and monitors were programmed to record blood
pressure every 30minutes. Patients completed a diary card and
pressed the event marker on the monitor to identify sleep-wake
cycle. Patients with a 24-hour average blood pressure ≥140/85
mm Hg were deﬁned as hypertensive.
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All subjects underwent complete M-mode, 2-dimensional, and
Doppler echocardiography to determine left ventricular ejection
fraction (LVEF), left ventricular mass (LVM), and valve function.
The LVEF was calculated according to the modiﬁed Simpson
rule. LV dimensions were acquired in systole and diastole by
measurement of the septal wall thickness (SWT), posterior wall
thickness (PWT), and LV internal diameter (LVID) from the
parasternal long-axis view. We calculated LV mass as 0.8 {1.04
[(LVIDd+PWTd+SWTd)3 (LVIDd)3]}+0.6g.[30] LV mass was
indexed to the body surface area calculated as 0.0235height
(cm)0.42246weight (kg)0.51456 to derive the LV mass index
(LVMI, g/m2).[31] LVH was deﬁned according to the previously
establishedcriterion (LVMI>125g/m2 formenandLVMI>110g/
m2 for women).[32] Anteroposterior left atrium (LA) diameter was
obtained using a parasternal long-axis view and LA area using a
4-chamber apical window in a 2-dimensional echocardiography.
2.4. Blood sampling
Venous blood samples were collected after overnight fasting in
Becton Dickinson Vacutainer CPT tubes with sodium heparin.
Plasma was immediately separated by centrifugation (3000 RCF/
4°C/10min) and aliquots were stored at 80°C. Total plasma
cholesterol was measured by the CHOD-PAP method with kit
A11A01634 (HORIBA ABX Diagnostic, Montpellier, France).2.5. NMR analysis
NMR analysis was performed as previously reported.[33] Brieﬂy,
1 plasma aliquot was used for diluted plasma 1H NMR analysis
(250mL was diluted into 755mL ﬁnal mixture of 500mL 0.9%
saline in D2O and 5mL 100mM sodium 3-(trimethylsilyl)
propionate-2,2,3,3-d4 (TSP)) immediately before the NMR
spectra acquisition. A second plasma aliquot was submitted to
an extraction process to isolate the hydrophilic and lipophilic
plasma metabolites into 2 separate fractions that were analyzed
serially on the following day. Simultaneous extraction of
lipophilic and polar metabolites was performed with ice-cold
methanol, chloroform, and water (2:2:1.3, v/v/v). The aqueous
fraction of the extract was reconstituted in 600mL of D2O
phosphate-buffered solution with 10mL of a 10mM 3-(trime-
thylsilyl)-1-propanesulfonate sodium salt (TMPS) before NMR
analysis. The organic fraction of the extract was reconstituted in
1mL CDCl3 with 10mL TCB (100mM) and maintained under
nitrogen atmosphere at 80°C until NMR analysis. 1H NMR
spectra were recorded at 300K on a Bruker Avance DRX 600
spectrometer operating at 600.13MHz and equipped with a 5
mm triple axis inverse (TXI) gradient cryoprobe. Four plasma
spectra were acquired for each patient: spectrum of diluted
plasma sample acquired with presaturation of the water signal
and using 1-pulse sequence, namely the Zg-spectrum; spectrum
of diluted plasma acquired with presaturation of the water and
carr-purcell-meiboom-gill spin-echo sequence, namely the cpmg-
spectrum; spectrum of aqueous fraction of the plasma extract,
namely the Aq-spectrum; spectrum of the organic fraction of the
plasma extract, namely the Org-spectrum. The Zg-spectrum and
CPMG spin-echo sequence (cpmg-spectrum) had an echo loop
time (2np) of 320milliseconds. A total of 64 transients were
sampled with a spectral width of 12ppm, 32K data point on time
domain (2.3seconds acquisition time) and 2.5seconds additional
relaxation delay. Spectra of aqueous and organic fractions were
serially acquired using an automatic sampling changer (B-ACS360). Spectra of aqueous fractions (Aq. spectrum) were obtained
with similar parameters to the one-pulse spectrum of the diluted
plasma whereas spectra of the organic fraction (Org. spectrum)
were acquired with an additional delay of 4seconds and without
solvent suppression. 1H NMR spectra were processed using the
TOPSPIN (version 2.1, Bruker BioSpin SA, France, Wissem-
bourg) and AMIX (Bruker Analytik, Rheinstetten, Germany)
software packages. Typical processing parameters were 65K
zero-ﬁlling and an exponential apodizing function (0.3Hz)
applied before Fourier transformation. Phase and base-line
corrections of spectra were performed by operator and referenced
with AMIX software to methyl resonance of TMPS, lactate or
TCB for diluted plasma, aqueous fraction, and organic fraction,
respectively. 1H NMR spectra were processed using the
TOPSPIN (version 2.1, Bruker BioSpin SA) and AMIX (Bruker
Analytik) software packages. To perform data reduction and
pattern recognition, each of the 4 NMR spectra obtained per
patient were bucketed to obtain spectral data sets using the
AMIX (Bruker Analytik) software package. The generated
variables were identiﬁed with the central chemical shift value
of the bins as sufﬁx and Zg, cpmg, Aq, or Org as preﬁxes. This
raw data matrix was exported into the SIMCA-P+ (version 12.0,
Umetrics, Umea, Sweden) software to be separately orthogonal-
ized with an orthogonal signal correction (OSC) ﬁltering function
prior fusioned in a normalized matrix of 672 rows (X-block) and
126 lines. To maximize separation between the groups, partial
least squares discriminant analysis (PLS-DA) was performed by
using LV mass index as Y (Y-block). The statistical results
obtained by PLS-DA methods are able to detect which variables
in the X-block are relevant to determine the dependent variables
(Y-block) by means of the variable inﬂuence on projection
parameter (IP) values. The IP values reﬂect, in fact, the
importance of terms in the model both with respect to Y, that
is, its correlation with all the responses, and with respect to X.2.6. Statistical analysis
Continuous variables are presented as mean±SD and categorical
as numbers and percentages. Continuous variables were
compared with the use of 1-way ANOVA followed by Tukey
multiple comparison test when P-value was <0.05, or Kruskal–-
Wallis rank sum test followed by Dunn multiple comparisons test
(for a P-value <0.05), when normality or an equal variance test
failed. Categorical variables were compared with the use of
the Pearson Chi-square (sigma stat). Statistical analyses were
performed using Graph Pad Prism software 6.0 (www.graphpad.
com). Receiver operating characteristic (ROC) curve analysis was
performed using MedCalc 15.8 software (www.medcalc.be).3. Results
3.1. Study population
The ﬂowchart for patient inclusion is shown in Fig. 1. Patient’s
characteristics are shown in Table 1. Hypertensive patients were
older, had a higher BMI, and were more likely to have diabetes
and dyslipidemia. The sex distribution, renal function, and LV
ejection fractions were similar across all cohorts. Control
individuals had lower rates of diabetes, dyslipidemia, or obesity
than the hypertensive cohort. However, within the hypertensive
cohort the rates of these pathologies were similar. The
hypertensive population had a systolic blood pressure (SBP) of
149±20mm Hg versus 125±13mm Hg for the control group.
600 Consecutive Patients 
Cardiology Departement
(IBLOMAVED COHORT)
HTN
n=221
Non HTN
n=379
Patients 
included
in the study
n=96
24 Healthy
Controls
Paents non included,
non meeng the inclusion criteria (n=125):
-Smokers (n=25)
-Heart Failure or Atrial Fibrillaon (n=38)
-Valvular Disease (n=37)
-Myocardium necrosis (n=21)
-Hemoglobinopathies (n=2)
-Dialysis (n=2)
48 HTN
no LVH
48 HTN
LVH
Non Healthy
n=355
Figure 1. Flow diagram of the study. The Identiﬁcation Of Blood Markers For
Asymptomatic Ventricular Dysfunction (IBLOMAVED) cohort was used for this
study. HTN=arterial hypertension, LVH= left ventricular hypertrophy.
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number of antihypertensive treatments in comparison to
hypertensive patients with normal LV size, and, although not
statistically signiﬁcant, had 1mm Hg of SBP and 4mm Hg of
diastolic blood pressure (DBP) lower than hypertensive patientsTable 1
Clinical characteristics, echocardiographic parameters, and hemody
Parameter
Group 1, control
(n=24)
Group 2, HTN normal
LV size (n=48)
Age, y 53±10 62±10
Female, % (n) 42 (10) 50 (24)
BMI, kg/m2 24±3 28±5
SBP, mmHg 125±13 149±21
DBP, mm Hg 79±9 88±12
Diabetes, n 0 10 (21%)
Dyslipidemia, n 0 28 (58%)
Obesity, n 0 13 (27%)
Cockcroft, mL/min 77±8 78±9
LV ejection fraction, % 69±7 69±7
LV mass indexed, g/m2 74±18 81±18
h/r 36±5 37±4
E/A ratio 1.3±0.4 0.9±0.2
Deceleration time, ms 180±39 222±53
E/Ea ratio 7.1±3 8.2±2
LA area, cm2 16.2±3 19.2±4
LA diameter/BSA, mm/m2 17.2±1.2 18.3±2.5
Antihypertensive medication, % (n)
ACE I 0 (0) 27 (13)
ARBs 0 (0) 31 (15)
Diuretics 0 (0) 40 (19)
BBs 0 (0) 40 (19)
AAs 0 (0) 4 (2)
CCBs 0 (0) 40 (19)
CAAs 0 (0) 10 (5)
Total antihypertensive medications 0 (0) 92
Average±SD.
AAs= aldosterone antagonists, ACE I= angiotensin-converting-enzyme inhibitors, ARBs=angiotensin II
centrally acting antihypertensive drugs, CCBs= calcium channel blockers, DBP=diastolic blood pressure, E
annular diastolic velocity ratio, h/r= thickness/radius ratio, HTN= arterial hypertension, LA= left atrium,
4with normal LV size. Patients with LV hypertrophy had greater
LV mass and a LV thickness/radius ratio (h/r) of 52±8, both
signiﬁcantly greater (P<0.001) versus hypertensive patients
without LV remodeling and compared to healthy controls.
Lastly, hypertensive patients with and without LVH had higher
deceleration time, early diastolic transmitral velocity to early
mitral annular diastolic velocity ratio (E/Ea ratio), and left atrial
area, but lower early/late ventricular ﬁlling velocities ratio (E/A
ratio) compared to control. E/A ratio and LA area were not
different between the 2 hypertensive groups, while LA diameter
index tended to increase in the LVH group (P=0.0567).
3.2. 1H NMR metabolomic proﬁling
Data from the 1H NMR spectra of plasma were analyzed using
partial least squares discriminant analysis (PLS-DA). A PLS-DA
score plot of spectral data revealed sample clustering according to
the clinical status (Fig. 2A). In the loading plot (Fig. 2B),
discriminant variables clearly separate the hypertensive patients
with LVH, hypertensive patients with normal LV size, and
healthy subjects into unique cohorts. The 10 most discriminating
variables in the PLS-DA corresponded to speciﬁc signals (framed
in red in Fig. 2B) from plasma lipids. Comparing the distribution
of these variables with the distribution of individuals, we found
that variables called orgOSC: 1.2 and 1.39 had a greater mean
value in the group of hypertensive patients with LVH, while
orgOSC: 0.91 and 0.97 were higher in the group of hypertensive
patients with normal LV size and control individuals. Signalsnamic levels.
Group 3, HTN LVH
(n=48)
P,
Group 1 vs 2
P,
Group 1 vs 3
P,
Group 2 vs 3
65±10 0.0014 <0.0001 0.3092
22 (11) 0.9999 0.3689 0.0191
28±4 0.0008 0.0008 0.9999
148±20 <0.0001 <0.0001 0.9650
84±12 0.0061 0.1936 0.2065
14 (29%) 0.0873 0.0095 0.5497
24 (50%) <0.0001 <0.0001 0.6365
14 (29%) 0.024 0.0136 0.966
78±7 0.8729 0.8729 >0.9999
68±9 >0.9999 0.8673 0.8079
115±33 0.5072 <0.0001 <0.0001
52±8 0.7887 <0.0001 <0.0001
0.8±0.3 <0.0001 <0.0001 0.2119
246±77 0.0203 0.0001 0.1418
8.8±2 0.1239 0.008 0.3887
19.3±6 0.0346 0.0278 0.9942
19.5±3 0.1955 0.0012 0.0567
42 (20) 0.0032 <0.0001 0.197
48 (23) 0.0014 <0.0001 0.1436
50 (24) 0.001 <0.0001 0.4118
50 (24) 0.001 <0.0001 0.4118
0 (0) 0.5493 >0.999 0.4974
46 (22) 0.0001 <0.0001 0.681
17 (8) 0.1619 0.0457 0.5523
121 <0.0001 <0.0001 0.0202
receptor blockers, BBs=beta-blockers, BMI=body mass index, BSA=body surface area, CAAs=
/A= early/late ventricular ﬁlling velocities ratio, E/Ea= early diastolic transmitral velocity to early mitral
LV= left ventricular, LVH= left ventricular hypertrophy, SBP= systolic blood pressure.
Figure 2. PLS-DA analysis of 1H NMR spectral data. (A) PLS-DA t1/t2 score plot derived from 1H NMR metabolic proﬁling. Gray represents control, blue
hypertensive patients without LV hypertrophy (LVH), and red hypertensive with LV hypertrophy (alphanumeric codes represent individuals). The ellipse deﬁnes
the Hotelling t2 conﬁdence region (95%). (B) PLS-DA weight plot (w∗c1 vs w∗c2). Metabolites are indicated with an alphanumeric code. The 10 most
discriminating metabolites were framed in red and correspond to speciﬁc signals from plasma lipids. Metabolites in the lower left contribute considerably to the
deﬁnition of the group of hypertensive patients with LVH, while those in the upper right contribute to deﬁne the group of hypertensive patients with normal LV size
or healthy control.
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chemical shift and corresponded to protons located in the
methylene (–CH2–) group (1.2–1.39) and in the methyl (–CH3)
group (0.91–0.97) of aliphatic chains from plasma lipids in the
organic fraction of plasma. In more detail, signals in the organic
fraction came from a peak of the 1H NMR spectra at 1.3ppm
(part per million) for the hypertensive patients with LVH, while
the signals for hypertensive patients with no LVH and healthy
controls came from a peak at 0.9ppm.
Chemical groups derived from the aliphatic chains of plasma
lipids are shown in Fig. 3. The methylene/methyl ratio was found
to be signiﬁcantly higher in hypertensive patients with LVHwhen
compared to hypertensive patients with normal LV size or to
control individuals (Fig. 4). The methylene/methyl ratio was5similar between hypertensive patients with normal LV size and
control individuals.
3.3. Cholesterol level
There was no difference between the 3 groups for cholesterol
plasma levels (Fig. 5).
3.4. Methylene/methyl ratio as predictor of left ventricular
hypertrophy
The diagnostic performance of the methylene/methyl ratio with
respect to LV mass index for LVH was evaluated using ROC
curve analysis (Fig. 6). The methylene/methyl ratio showed an
R=8/1 
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Figure 3. Methylene (–CH2–) and methyl (–CH3) moieties of aliphatic chains
from plasma lipids ratio (R). Formulae illustrate –CH2–/–CH3 ratios according to
the fatty acid chain length. Yellow points represent methylene (–CH2–).
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Figure 4. Methylene/methyl ratio in aliphatic lipid chains from plasma lipids of c
hypertensive patients with LV hypertrophy (HTN LVH). The methylene/methyl ratio
control. ∗∗∗P<0.001.
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6area under the curves (AUCs) of 0.703 (95% CI: 0.601–0.792;
P<0.001). The optimum cut-off point determined by the Youden
index was at 2.337, with 52.08% sensitivity and 85.42%
speciﬁcity. The positive and negative predictive values were
78.13% and 64.06%, respectively.
4. Discussion
Prolonged hypertension may result in LV structural remodeling,
alteration of cardiac function, and chronic heart failure.[2] Early
detection and treatment of LV hypertrophy in hypertensive
patients is important in order to prevent the progression toward
advanced cardiac disease. Cardiac hypertrophy biomarkers could
be a quick, sensitive and cost-effective tool to complement the use
of echocardiography in differentiating hypertensive patients with
LV remodeling from those with normal LV size. Such a
biomarker may be able to help in the screening of hypertensive
patients because a simple blood test could rule-out the presence of
LV structural remodeling. This situation would optimize the use
of echocardiography for conﬁrmation of LV structural remodel-
ing and help clinicians adapt therapeutic strategies to improve a
patient’s life expectancy.
We looked for plasma biomarkers of left ventricular remodel-
ing in hypertensive patients using plasma metabolomics. Plasma
offers the advantage of representing an “average” of tissue
biochemical information and is commonly available in clinical
practice. Discriminant variables were identiﬁed as signals from
the methylene and methyl moieties of plasma lipid aliphatic
chains. The methylene/methyl ratio, an indicator of the mean
aliphatic lipid chain length, was increased in the plasma of
hypertensive patients with left ventricular remodeling. Long-
chain fatty acids are the preferred substrate for energy provision
in the normal heart. The higher concentration of long-chain fatty
acids in the plasma of hypertensive patients with LVH could
reﬂect an impairment of their utilization at the myocardial level.
Indeed, patients with very long-chain acyl-CoA dehydrogenase
(VLCAD) deﬁciency, the enzyme responsible for the catabolism
of fatty acids with an acyl chain length between 14 and 18rm a l L V s ize H TN LVH
* * *
* * *
ontrol, hypertensive patients with normal LV size (HTN normal LV size) and
is higher in the HTN LVH group compared to HTN normal LV size group and
[34]
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Figure 5. Plasma cholesterol concentration in control, hypertensive patients
with normal LV size (HTN normal LV) and hypertensive patients with LV
hypertrophy (HTN LVH). No difference was found among groups.
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proﬁles from animals and patients with VLCAD deﬁciency are
characterized by large accumulations of long chain acyl
carnitines.[35,36]
Several investigations in spontaneously hypertensive
rats[16,37,38] and in humans with essential hypertension[22] have
proposed a direct link between decreased myocardial fatty acid
transport and a prohypertrophic cardiac response. A recent studyFigure 6. Receiver operating characteristic (ROC) curve analysis of methylene/me
the curve) is 0.703.
7found that the heart of hypertensive humans with LV remodeling
expresses a truncated form of peroxisome proliferator-activated
receptor a (PPARa).[18] PPAR-a is a key transcriptional regulator
of the expression of fatty acid carriers and b-oxidation genes.
Increased expression of the truncated PPARa is associated with
decreased expression of the PPARa target genes involved in fatty
acid transport and oxidation.[18] Moreover, decreased PPARa
expression and/or activity in the heart could be linked to the
development of local inﬂammation and ﬁbrosis.[39] Supporting
the concept that defects in fatty acid transport and oxidation play
an important role in ventricular hypertrophy is the fact that
mutations in the fatty acyl translocase CD36, a plasma
membrane transporter involved in the uptake of long chain
fatty acids by cardiomyocytes, have been linked to cases of
inherited hypertrophic cardiomyopathy.[40] Further, the inhibi-
tion of myocardial fatty acid metabolism has been reported as an
independent predictor of the cardiac hypertrophic response in
hypertensive patients evaluated by PET scan.[22]
The use of the ROC curve analysis with the methylene/methyl
ratio data allowed us to describe the performance of the
biomarker. Despite a modest sensitivity (52%) this biomarker
displayed high speciﬁcity (>85%) in detecting LVH, supporting
the diagnostic value of this biomarker. It has been previously
reported that cholesterol, insulin resistance, and adiposity are
signiﬁcantly correlated with left ventricular mass in hypertensive
patients.[41,42] In our study, there was no signiﬁcant difference in
insulin levels, obesity, or dyslipidemia between the hypertensivethyl ratio used to identify LVH in hypertensive population. The AUC (area under
Evaristi et al. Medicine (2016) 95:46 Medicinegroups. Moreover we did not ﬁnd any difference in cholesterol
levels between hypertensive patients with or without left
ventricular remodeling. This is in agreement with a study
conducted in Japanese patients where total cholesterol was not
found associated to LVH in essential hypertension.[42] In our
study, hypertensive patients with LV remodeling maintained a
normal LV ejection fraction. This ﬁnding agrees with previous
reports of increased ventricular mass index and relative wall
thickness with preserved ejection fraction.[43] In fact, LVH
secondary to hypertension is a physiological process of
compensation to minimize wall stress, allowing preservation of
LVEF.[2] However, concentric LVH commonly precedes dilated
cardiac failure in patients with hypertension.[2]
An abnormal diastolic relaxation in the absence of systolic
impairment is often seen in patients with hypertension, and a
reduction in compliance is observed when LVH occurs.[44]
Attention has recently been concentrated on echocardiographic
measurement of left atrial size, as it frequently correlates with
LVH and is predictor of cardiovascular events.[45] In our study,
there were no differences in standard parameters used for
diastolic and left atrial function evaluation in the 2 groups of
hypertensive patients. However, left atrial diameter index tended
to increases in our hypertensive patients with LVH compared to
hypertensive patients with no LV remodeling. This evidence
suggests a diastolic dysfunction in hypertensive patients with LV
remodeling and points out the limitations[45] of current
techniques such as Doppler and 2D echocardiography in the
evaluation of diastolic[46] and left atrial function.[47] New tools
such as 2D speckle tracking echocardiography[48] should be
useful for early detection of cardiac malfunction due to arterial
hypertension.[48–50]
A recent study has reported that exercise-induced arterial
hypertension leads to myocardial hypertrophy in a similar way to
that found in pathological conditions with arterial hyperten-
sion.[51] As some biomarkers, both cardiac troponin I and
NTproBNP have been found to be increased in runners,[52] it
would be interesting to measure the level of the methylene/methyl
ratio in these athletes. In addition, low-intensity exercise was
shown to unmask hypertension in patients with apparent normal
clinic blood pressure but elevated blood pressure outside the
ofﬁce environment.[53] We used a 24-hour ambulatory blood
pressure measurement and did not evaluate patients this way in
our study. However, after low-intensity exercise testing of
patients, methylene/methyl ratio monitoring could provide useful
information about possible LV remodeling.
The absence of other physiological differences between the 2
hypertensive groups in our study reinforces the possibility that
the methylene/methyl ratio may be used as a diagnostic and
screening tool for hypertensive left ventricular remodeling.
Moreover, methylene/methyl ratio was not different between
controls and hypertensive patients without LVH. Although
evidence is currently lacking, we believe that methylene/methyl
ratio is only sensitive to the LV remodeling and thus not different
in normal participants and hypertensive patients that did not
show any clinical manifestation toward LV remodeling during
the screening.
Our study proposes plasma methylene/methyl ratio as a
metabolic biomarker for the detection of LV remodeling in
hypertensive patients. However, as this result stems from a small
single center cohort, further validation through a large
international multicenter study is needed. Secondly, the timing
of the methylene/methyl ratio modiﬁcation, that is, whether an
increase in the methylene/methyl ratio can be detected in8hypertensive patients at risk to develop LVH or whether it is
only a post-LVH consequence, remains to be established.
Thirdly, as it is known that genetic variants and polymorphisms
are implied in hypertensive related cardiovascular
complications,[54–57] genetic variants of key fatty acids metabolic
enzymes regulating the hypertrophic phenotype need to be
evaluated. Lastly, potential confounders to increases in the
methylene/methyl ratio need to be determined and the precise
molecular mechanisms leading to the alteration of fatty acid
species in the bloodstream remain to be investigated.Acknowledgments
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